Peter Evan Harwin - 26 Jun 2024 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Director
Signature
/s/ Jennifer Tousignant, Attorney-in-Fact for Peter Evan Harwin
Issuer symbol
VRDN
Transactions as of
26 Jun 2024
Net transactions value
$0
Form type
4
Filing time
28 Jun 2024, 16:05:06 UTC
Previous filing
13 Jun 2024
Next filing
05 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Award $0 +21,000 $0.000000 21,000 26 Jun 2024 Common Stock 21,000 $12.31 See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests in full upon the earlier to occur of (i) June 26, 2025 or (ii) the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board.
F2 Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Remarks:

Exhibit 24 - Power of Attorney